High-Dose Omega-3 Linked to Atrial Fibrillation Risk
Key Takeaways
- In a pooled randomized setting spanning 35 trials, a statistically significant atrial fibrillation signal was reported only among participants at high cardiovascular risk receiving more than 1500 mg/day of EPA/DHA.
- That high-risk, high-dose subgroup showed an absolute atrial fibrillation risk difference of 0.8%.
- Lower-dose EPA/DHA did not appear to increase atrial fibrillation risk, including in high-risk populations.
- The remaining dose-risk strata were not statistically significant in the pooled analysis.
An updated meta-analysis examined omega-3 fatty acid treatment and new-onset atrial fibrillation (AF) in randomized controlled trials (RCTs). The evidence base included 35 randomized controlled trials, 37 data sets, and 114592 individuals. The primary outcome was new-onset AF.
Eligible trials evaluated docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) at daily doses of at least 500 mg/day for at least 12 months in participants aged 50 years or older, excluding known AF or atrial flutter at baseline where possible.
A prespecified framework separated omega-3 dose above versus below 1500 mg/day together with background cardiovascular disease risk status. The analysis was designed to test whether dose and patient risk profile changed the AF signal.
Among patients at high cardiovascular risk receiving more than 1500 mg/day of EPA/DHA, the pooled odds ratio for new-onset AF was 1.43 with a 95% confidence interval of 1.14 to 1.79. Investigators framed that finding as a dose- and risk-stratified pattern rather than a class-wide effect. The statistically significant signal was confined to that high-risk, higher-dose subgroup.
The same high-risk, higher-dose subgroup had an absolute risk difference of 0.8% with a 95% confidence interval of 0.4% to 1.1%. The other three dose-risk strata did not show statistically significant associations in the pooled estimates. The overall pattern remained separated by both treatment intensity and baseline cardiovascular risk.
The reported findings support a dose- and risk-stratified pooled association rather than a uniform effect of omega-3 therapy on atrial fibrillation risk. The signal therefore separates lower-dose use from the higher-dose finding rather than extending atrial fibrillation risk to all omega-3 exposure.
The authors concluded that high-dose EPA/DHA was associated with increased AF risk in patients at high cardiovascular disease risk, whereas low-dose EPA/DHA did not appear to increase AF risk even in high-risk populations. They called for further prospective study of possible higher-dose risk alongside potential benefits. The conclusion remained dose- and risk-stratified within the pooled randomized evidence.
Clinician Questions
Which omega-3 trials were eligible for the atrial fibrillation meta-analysis?
Eligible omega-3 therapy trials in the atrial fibrillation meta-analysis were randomized studies of docosahexaenoic acid and eicosapentaenoic acid at daily doses of at least 500 mg/day, with treatment duration of at least 12 months and participants aged 50 years or older; those criteria define the populations to which the pooled signal directly applies.
Did the omega-3 atrial fibrillation meta-analysis include patients with existing AF or atrial flutter?
Eligible omega-3 atrial fibrillation trials excluded known atrial fibrillation or atrial flutter at baseline where possible, and the pooled analysis defined its primary outcome as new-onset atrial fibrillation.
What remains uncertain about higher-dose EPA/DHA and atrial fibrillation risk after this meta-analysis?
The remaining question is whether higher-dose EPA/DHA carries increased atrial fibrillation risk while also delivering potential benefits; the authors said further prospective studies are needed to clarify that balance.